Between Sept News Today

1. Post-ERCP pancreatitis was more common in the indomethacin alone group compared to indomethacin plus stent group. 2. The benefit of stent placement was prominent among patients at high risk for pancreatitis. Evidence Rating Level: 1 (Excellent) Study Rundown: In high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), combining rectal indomethacin with prophylactic pancreatic stent placement

1. Duration of organ support or death at 30 days was lower in the conservative oxygenation group compared to the liberal oxygenation group. 2. Prespecified adverse events were also lower in the conservative oxygenation group. Evidence Rating Level: 1 (Excellent) Study Rundown: The optimal systemic oxygenation target for critically ill children remains uncertain, with liberal

1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is designed

1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is

1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in the placebo group. 2. Any-grade adverse events were more common among the semaglutide group with the most common being mild-to-moderate severity gastrointestinal symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with overweight or obese body-mass-indices (BMIs)

1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in the placebo group. 2. Any-grade adverse events were more common among the semaglutide group with the most common being mild-to-moderate severity gastrointestinal symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with overweight or obese

1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced fitness. Data

1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups. 2. The majority of treatment-related adverse events were mild-to-moderate in nature. Evidence Rating Level: 1 (Excellent) Study Rundown: Glucagon-like peptide (GLP-1) receptor agonists are emerging as first-line therapies for the management of type 2 diabetes (T2D). Currently, semaglutide

1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced

1. Target refractive outcome was achieved in 97% of ISBCS and 98% of DSBCS patients. 2. Societal costs for ISBCS were $507 (€403) lower, on average, compared to DSBCS. Evidence Rating Level: 1 (Excellent) Study Rundown: Cataract surgery accounts for a large proportion of age-related visual surgeries worldwide. Delayed sequential bilateral cataract surgery (DSBCS) is